Brief: Cognition Therapeutics Presented Preclinical Findings Showing That Sigma-2 Receptor Modulators Rescue Trafficking Deficits In Retinal Pigment Epithelial Cells In Model Of Dry AMD
03/05/2022 13:37
May 3 (Reuters) - Cognition Therapeutics Inc CGTX.O :
* COGNITION THERAPEUTICS PRESENTED PRECLINICAL FINDINGS
SHOWING
THAT SIGMA-2 RECEPTOR MODULATORS RESCUE TRAFFICKING DEFICITS IN
RETINAL PIGMENT EPITHELIAL CELLS IN MODEL OF DRY AMD
Source text for Eikon: ID:nGNX8V4prg
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB